GLP-1s are driving returns on R&D investments for Big Pharma, report says
Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...
Novo adds to obesity drug pipeline via $200M deal with China-based biotech
The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
pharmaphorum5d
Amgen's big reveal of obesity data falls a little flat
Despite that assessment, shares in Amgen lost nearly 5% of their value ... better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below ...
The Mag 7 Are Dead Money. 6 ‘Megacap’ Stocks to Buy Instead.
There is a laundry list of companies that have market capitalizations of more than $100 billion that look like buys ...
MM&M2d
What did Big Pharma CEOs get paid in 2024?
GSK said the proposal would result in Walmsley sitting in the lower and median quartile of its biopharma peer group, which includes AstraZeneca, Amgen, Bayer and Moderna ... Lilly’s popular weight ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
NBC New York1d
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes shot Mounjaro – which targets GLP-1 but also activates ...